Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA

This article was originally published in The Pink Sheet Daily

Executive Summary

Relatively new to the diabetes space, Boehringer Ingelheim is trying to rapidly distinguish itself in a crowded field with four products each addressing a different patient need.

Advertisement

Related Content

Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS074307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel